Improving Individual Glycemic Response With Exercise Intensity (INTENSITY)

May 16, 2022 updated by: Martin Senechal, University of New Brunswick
Large interindividual variability exists in the glycemic response to exercise program, resulting in a subset of individuals known as exercise non-responders (NRs). Increasing the intensity of an exercise intervention has been proposed as one method for rescuing NRs by producing beneficial changes. However, this theory has not been tested on NRs classified using glycemic outcomes. This study will evaluate if increasing the intensity of an exercise intervention will elicit a response within previous exercise NRs.

Study Overview

Detailed Description

Exercise can effectively slow the progression towards Type 2 diabetes (T2D). However, data suggest large interindividual variability exists in glycemic response to exercise, resulting in a subset of individuals known as exercise non-responders (NRs). Emerging research proposes that altering the parameters of an exercise intervention to provide a sufficient stimulus can elicit a response in those previously identified as NRs. To date, no research has attempted to rescue previously classified NRs based on glycemic outcomes by altering the parameters of an exercise intervention.

This study will implement an exercise program targeted at achieving the Canadian Physical Activity Guidelines, and calculate the number of NRs. We will then evaluate if increasing the intensity of exercise will elicit response to the treatment in the NRs.

Sixty adults living with prediabetes or T2D will be recruited into one of a control group, or an exercise group. The exercising participants will begin a 16-week exercise intervention, targeted at achieving 150 minutes of moderate to vigorous intensity (equating to 4.5 METs) aerobic physical activity per week. Following the 16-week exercise program, participants will be randomized into two groups, each completing an additional 12 weeks of exercise. The first will maintain the same time and intensity, while the other will complete the 150 minutes per week at an intensity equal to 6.0 METs. Randomization will occur in blocks in order to ensure an equal number of NRs in each group.

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 5A3
        • University of New Brunswick

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  1. Community-dwelling adults aged 19 years or older.
  2. Currently living with prediabetes or T2DM as diagnosed by a physician and confirmed by an HbA1c value of 5.7% or above, as verified by duplicate testing.
  3. Not currently partaking in a self-reported regular physical activity regimen, defined as consistent participation in running or jogging activity, attending physical activity or exercise classes on a weekly basis, or averaging 10,000 steps per day or more over the course of 7 days.

Exclusion criteria:

  1. Self reported as currently diagnosed as having, or being treated for, low iron concentrations or anemia.
  2. Diagnosed with any red blood cell altering condition.
  3. Currently living with any cardiovascular disease which would impact the ability to safely participate in exercise training.
  4. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track exercise intensity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Controls
The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
Experimental: Exercisers (Maintained)
The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.

Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.

Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).

Duration:

Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week

Week 17: Physiological Testing

Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week

All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.

Experimental: Exercisers (Increased Intensity)
The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.

Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.

Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).

Duration:

Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week

Week 17: Physiological Testing

Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week

All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise responders following initial program
Time Frame: Week 17
The number of responders to the original 16-week exercise program, based on improvement in glycated hemoglobin
Week 17
Exercise responders following additional exercise program
Time Frame: Week 30
The number of responders following the additional 12-week exercise program, based on improvement in glycated hemoglobin
Week 30

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sex
Time Frame: Baseline
Participant self-reported biological sex
Baseline
Family history of cardiovascular disease
Time Frame: Baseline
Self-reported family history of cardiovascular disease
Baseline
Family history of cardiometabolic disease
Time Frame: Baseline
Self-reported family history of cardiometabolic disease
Baseline
Current medication use
Time Frame: Baseline
Record of quantity and dose of current medications
Baseline
Physical activity patterns
Time Frame: Baseline
Participant self-reported physical activity patterns and daily step counts over a 7-day period.
Baseline
Daily step count
Time Frame: Baseline
Daily step count as recorded over a 7-day period
Baseline
Body mass
Time Frame: Baseline, week 17 and week 30
Body mass (kilograms)
Baseline, week 17 and week 30
Height
Time Frame: Baseline, week 17 and week 30
Height (centimetres)
Baseline, week 17 and week 30
Waist circumference
Time Frame: Baseline, week 17 and week 30
Waist circumference (cm)
Baseline, week 17 and week 30
Fat mass
Time Frame: Baseline, week 17 and week 30
Fat mass (kg)
Baseline, week 17 and week 30
Fat free mass
Time Frame: Baseline, week 17 and week 30
Fat free mass (kg)
Baseline, week 17 and week 30
Cardiorespiratory fitness
Time Frame: Baseline, week 17 and week 30
VO2 peak
Baseline, week 17 and week 30
Body mass index
Time Frame: Baseline, week 17, week 30
Weight (kilograms) and height (measured in centimetres and converted to metres) will be combined to report body mass index in kg/m^2
Baseline, week 17, week 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2019

Primary Completion (Actual)

July 31, 2021

Study Completion (Actual)

July 31, 2021

Study Registration Dates

First Submitted

December 21, 2018

First Submitted That Met QC Criteria

December 21, 2018

First Posted (Actual)

December 26, 2018

Study Record Updates

Last Update Posted (Actual)

May 18, 2022

Last Update Submitted That Met QC Criteria

May 16, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Maintained Exercise

3
Subscribe